Results of treatment of schizophrenia: Is the glass half full or half empty?

International Clinical Psychopharmacology

Volumn 14, Issue SUPPL. 3, 1999, Pages

  Kissling, Werner ^a   Leucht, Stefan ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Compliance; Costs; Medical decision making; Naturalistic studies; Outcome; Relapse; Research; Schizophrenia

Indexed keywords

CONFERENCE PAPER; HEALTH CARE COST; HUMAN; MEDICAL DECISION MAKING; MEDICAL PRACTICE; MEDICAL RESEARCH; PATIENT COMPLIANCE; PRIORITY JOURNAL; RELAPSE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EVIDENCE-BASED MEDICINE; HUMANS; SCHIZOPHRENIA;

EID: 0032812588     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199906003-00003     Document Type: Conference Paper

References (8)

1. Gaebel W, Pietzcker A (1985). One-year-outcome of schizophrenic patients - the interaction of chronicity and neuroleptic treatment. Pharmacopsychiatry 18:235-239.
2. Kane JM, Rifkin A, Woerner M, Reardon G, Kreisman D, Blumenthal R, et al. (1985). High dose versus low dose strategies in the treatment of schizophrenia. Psychopharmacol Bull 21:533-537.
3. Kissling W (1991). Guidelines for neuroleptic relapse prevention in schizophrenia. Berlin: Springer.
4. Kissling W (1994). Compliance, quality assurance and standards for relapse prevention in schizophrenia. Acta Psychiatr Scand suppl 382:16-24.
5. Kissling W (1998). Die Kosten psychiatrischer Erkrankungen (1): cost and benefit. Neurotransmitter 37:35-36.
6. Kissling W, Seemann U (1998), Die Kosten psychiatrischer Erkrankungen (2): Teure Sparmaßnahmen. Neurotransmitter 38:35-36.
7. Kissling W, Höffler J, Seemann U, Müller P, Rüther E, Trenckmann U, et al. (1999). Die direkten and indirekten Kosten der Schizophrenie. Fortschr Neurol Psychiat 67: 29-36.
8. Ten Horn GHMM (1985). Aftercare and readmission. A Dutch psychiatric case register study. Soc Psychiat 19:111-116.